Clinical Trial Update: Targeting ODC as an Immunotherapeutic Target in STK11 (LKB1) Pathway-Deficient NSCLC (DFMO) [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating difluoromethylornithine (DFMO) as an immunotherapeutic target in STK11-deficient non-small cell lung cancer has been suspe…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Cancer
• Non-small Cell Lung Cancer

Drugs mentioned

• DFMO (difluoromethylornithine)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Non Small Cell Lung Cancer, Lung Cancer | Phase 1, Phase 2 | Status: SUSPENDED